Stocktoria
Zentalis Pharmaceuticals, Inc. ZNTL
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-04-03
Zentalis Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | — | — | — |
| R&D expense | $107.3M | $167.8M | $189.6M | $172.7M | $175.6M | $84.9M | $38.4M |
| Operating income | -$152.8M | -$191.2M | -$299.5M | -$227.3M | -$216.5M | -$118.8M | -$46.8M |
| Income tax | $442,000 | $177,000 | -$601,000 | -$469,000 | -$297,000 | $444,000 | $15,000 |
| Net income | -$137.1M | -$165.8M | -$292.2M | -$236.8M | -$158.7M | -$117.8M | -$45.7M |
| EPS (diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 | $-4.19 | $-8.16 |
| Operating cash flow | -$125.2M | -$170.9M | -$207.8M | -$163.8M | -$154.1M | -$86.8M | -$39.1M |
| Free cash flow | -$125.2M | -$171.1M | -$208.4M | -$166.3M | -$160.2M | -$87.6M | -$39.5M |
| Cash & equivalents | $36.0M | $33.9M | $28.0M | $43.1M | $59.7M | $55.0M | $67.2M |
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M | $365.6M | $87.5M |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M | $32.2M | $19.1M |
| Shareholders' equity | $216.2M | $337.2M | $437.4M | $434.0M | $364.5M | $333.4M | -$73.3M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.